KH-001 ODT
Phase 2Small molecule
KH-001 ODT is one of 10 small molecule programs targeting Premature Ejaculation. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Premature Ejaculation
#DrugCompanyPhaseTrials
1Xylocaine
MMEDRx USA, Inc.
Approved
Viagra
VViatris Specialty LLC
Approved
Botox
AbbViePhase 3
Standard Treatment
Boehringer IngelheimPhase 3
BP1.4979
BBioprojet
Phase 2
Botox
RRevance Therapeutics, Inc.
Preclinical
KH-001 ODT
KKadence Bio
Phase 2
Dapoxetine Hydrochloride
Johnson & JohnsonPreclinical
Bont-a
SSir Run Run Shaw Hospital
Preclinical
Serotonin Reuptake Inhibitor (SSRI)
MMedipol University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Premature Ejaculation1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KH-001 ODT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- KKadence Bio